Navigation Links
Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
Date:12/1/2008

BASKING RIDGE, N.J., Dec. 1 /PRNewswire/ -- Regado Biosciences, Inc., announced today David J. Mazzo, Ph.D., President and Chief Executive Officer, will present at the 20th Annual Piper Jaffray Health Care Conference in New York, NY, on Tuesday, December 2, 2008, at 10:10am (Eastern Standard Time). Dr. Mazzo will discuss the Company's development pipeline, in addition to reviewing recent business and clinical developments.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the creation and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect. Enhanced control and flexibility allow physicians to meet the individual needs of patients independent of the setting. Regado is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.

Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.


'/>"/>
SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
2. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
3. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
4. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
5. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
6. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
7. BBM Announces Offer to Acquire YM BioSciences Inc.
8. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
9. LI-COR Biosciences and Mandel Scientific Company Inc. Announce Distribution Agreement
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 18, 2017 BD (Becton, Dickinson and Company) (NYSE: ... it will host a live webcast of its Annual Meeting of ... The webcast can be accessed from the BD corporate ... Tuesday, January 31, 2017. ... About BD BD is a global medical technology ...
(Date:1/18/2017)... 2017   Boston Biomedical , an industry leader ... cancer stemness pathways, will feature data from two clinical ... 2017 ASCO Gastrointestinal Cancers Symposium, held from January 19-21, ... Napabucasin is an orally-administered investigational agent designed to ... Cancer stem cells (CSCs) possess the property of stemness ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search firm Slone ... continued commitment to the advancement of the clinical trials segment. Hosted in Miami, ... clinical trial planning and management. , As executive talent specialists in the ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... new federally funded bio-focused Manufacturing Innovation Institutes (MII). U.S. Secretary of Commerce Penny ... Manufacturing Biopharmaceuticals (NIIMBL), and the Department of Defense has announced the award of ...
Breaking Biology Technology:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/12/2017)... 12, 2017 A new report by Allied Market Research, titled, ... biometric technology market is expected to generate revenue of $10.72 billion by 2022, with ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) In the ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol ... Capital Group, Inc., has been named to the elite "Forbes 30 ...  was one of 600 people in 20 fields nationwide to be ... of the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers ...
Breaking Biology News(10 mins):